Fasenra (benralizumab) has been on the market for 6 years and 210 days as of June 11, 2024, following its initial approval by the U.S. Food and Drug Administration (FDA).
Fasenra's Market Entry Timeline
Fasenra received its initial FDA approval on November 14, 2017, for the treatment of severe eosinophilic asthma. This significant milestone marked its entry into the pharmaceutical market. Since then, it has become an important biologic treatment option for patients managing this specific type of asthma.
Key approval dates for Fasenra include:
| Date | Event |
|---|---|
| Nov 14, 2017 | FDA approval for Fasenra (benralizumab) for severe eosinophilic asthma |
| Oct 4, 2019 | FDA approval for Fasenra Pen (benralizumab) Pre-Filled Auto-Injector for Self-Administration |
It is important to note that while the Fasenra Pen, a pre-filled auto-injector for self-administration, was approved in October 2019, the drug itself, Fasenra (benralizumab), was initially approved and thus on the market starting November 14, 2017.
What is Fasenra?
Fasenra is a biologic medication specifically designed to treat severe eosinophilic asthma. It is a monoclonal antibody that targets the interleukin-5 receptor alpha (IL-5Rα) on the surface of eosinophils, a type of white blood cell. By targeting and depleting eosinophils, Fasenra helps reduce inflammation in the airways, leading to fewer asthma attacks and improved lung function in eligible patients. It is typically administered as an add-on maintenance treatment for adults and adolescents aged 12 years and older.
Importance of Market Longevity for Medications
The duration a medication like Fasenra has been on the market offers several insights:
- Established Efficacy and Safety Profile: A longer market presence generally indicates that a drug has undergone extensive post-market surveillance, providing a more robust understanding of its long-term efficacy and safety in real-world clinical settings.
- Physician and Patient Experience: Healthcare providers and patients gain more experience with the drug, leading to better-informed treatment decisions and management strategies.
- Accessibility: Over time, market longevity can contribute to broader accessibility and integration into standard treatment guidelines.
